Your browser doesn't support javascript.
Fluvoxamine for symptomatic outpatients with COVID-19.
Wu, Peter E; Austin, Emily; Leong, Derek.
  • Wu PE; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Clinical Pharmacology and Toxicology (Wu), Department of Medicine, University of Toronto; Division of Emergency Medicine (Austin), St. Michael's Hospital; Ontario Poison Centre (Austin), Hospital for Sick Children; Department of Pharmacy (Leong), University Health Network, Toronto, Ont. peter.wu@uhn.ca.
  • Austin E; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Clinical Pharmacology and Toxicology (Wu), Department of Medicine, University of Toronto; Division of Emergency Medicine (Austin), St. Michael's Hospital; Ontario Poison Centre (Austin), Hospital for Sick Children; Department of Pharmacy (Leong), University Health Network, Toronto, Ont.
  • Leong D; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Clinical Pharmacology and Toxicology (Wu), Department of Medicine, University of Toronto; Division of Emergency Medicine (Austin), St. Michael's Hospital; Ontario Poison Centre (Austin), Hospital for Sick Children; Department of Pharmacy (Leong), University Health Network, Toronto, Ont.
CMAJ ; 194(7): E258, 2022 02 22.
Article in English | MEDLINE | ID: covidwho-1639151

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluvoxamine / Selective Serotonin Reuptake Inhibitors / COVID-19 Drug Treatment Limits: Adult / Humans Language: English Journal: CMAJ Journal subject: Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluvoxamine / Selective Serotonin Reuptake Inhibitors / COVID-19 Drug Treatment Limits: Adult / Humans Language: English Journal: CMAJ Journal subject: Medicine Year: 2022 Document Type: Article